Perspectives on Clinical and Preclinical Testing of New Tuberculosis Vaccines

Overview

Journal Clin Microbiol Rev

Publisher American Society for Microbiology

Specialty Microbiology

Date 2010 Oct 9

PMID 20930073

Citations 17

Authors

Arthur M Dannenberg Jr

Affiliations

Soon will be listed here.

Abstract

This review hopes to improve the selection of new tuberculosis (TB) vaccines by providing several perspectives on the immunization of humans, mice, guinea pigs, rabbits, and monkeys which have not usually been considered. (i) In human TB vaccine trials, the low rate of healing of Mycobacterium bovis BCG lesions (used as the control group) would distinguish individuals who might be helped by vaccination from the 95% who do not need it and would make these trials more conclusive. (ii) The rabbit immune response to Mycobacterium tuberculosis is much more effective in arresting tuberculosis than those of other laboratory animals, so pulmonary tubercle counting in rabbits should be included in all preclinical TB vaccine testing. (iii) Both delayed-type hypersensitivity (DTH) and cell-mediated immunity (CMI) are necessary to control the growth of M. tuberculosis. The testing of new TB vaccines in mice or in guinea pigs may not detect important antigens needed for human immunization. Mice respond poorly to tuberculin-like antigens that cause DTH. Guinea pigs respond poorly to antigens that cause CMI. Rabbits and humans respond well to both DTH and CMI antigens. Since monkeys are very susceptible to M. tuberculosis, they may not be as useful as rabbits for preclinical vaccine evaluation. (iv) Critical antigens (possibly ESAT-6 or CFP-10) might increase the immunity of the host to a greater extent than that produced by a natural M. tuberculosis infection and therefore would be useful in both prophylaxis and immunotherapy. Such critical antigens would increase the host's ability to neutralize key components of M. tuberculosis that enable it to survive in both laboratory animals and humans.

Citing Articles

Understanding the development of tuberculous granulomas: insights into host protection and pathogenesis, a review in humans and animals.

Lyu J, Narum D, Baldwin S, Larsen S, Bai X, Griffith D Front Immunol. 2024; 15:1427559.

PMID: 39717773 PMC: 11663721. DOI: 10.3389/fimmu.2024.1427559.

Next-Generation TB Vaccines: Progress, Challenges, and Prospects.

Zhuang L, Ye Z, Li L, Yang L, Gong W Vaccines (Basel). 2023; 11(8).

PMID: 37631874 PMC: 10457792. DOI: 10.3390/vaccines11081304.

B21 DNA vaccine expressing ag85b, rv2029c, and rv1738 confers a robust therapeutic effect against latent infection.

Weng S, Zhang J, Ma H, Zhou J, Jia L, Wan Y Front Immunol. 2022; 13:1025931.

PMID: 36569899 PMC: 9768437. DOI: 10.3389/fimmu.2022.1025931.

Potential Application of Exosomes in Vaccine Development and Delivery.

Huda M, Nurunnabi M Pharm Res. 2022; 39(11):2635-2671.

PMID: 35028802 PMC: 8757927. DOI: 10.1007/s11095-021-03143-4.

Neonatal and infant immunity for tuberculosis vaccine development: importance of age-matched animal models.

Ramos L, Lunney J, Gonzalez-Juarrero M Dis Model Mech. 2020; 13(9).

PMID: 32988990 PMC: 7520460. DOI: 10.1242/dmm.045740.

References

Dannenberg Jr A, Collins F . Progressive pulmonary tuberculosis is not due to increasing numbers of viable bacilli in rabbits, mice and guinea pigs, but is due to a continuous host response to mycobacterial products. Tuberculosis (Edinb). 2001; 81(3):229-42. DOI: 10.1054/tube.2001.0287. View

Barclay W, Anacker R, Brehmer W, Leif W, Ribi E . Aerosol-Induced Tuberculosis in Subhuman Primates and the Course of the Disease After Intravenous BCG Vaccination. Infect Immun. 1970; 2(5):574-82. PMC: 416053. DOI: 10.1128/iai.2.5.574-582.1970. View

Colditz G, Brewer T, Berkey C, Wilson M, Burdick E, Fineberg H . Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA. 1994; 271(9):698-702. View

Horwitz M, Harth G, Dillon B, Maslesa-Galic S . Commonly administered BCG strains including an evolutionarily early strain and evolutionarily late strains of disparate genealogy induce comparable protective immunity against tuberculosis. Vaccine. 2008; 27(3):441-5. PMC: 2657049. DOI: 10.1016/j.vaccine.2008.10.058. View

NORTH R, Ryan L, LaCource R, Mogues T, Goodrich M . Growth rate of mycobacteria in mice as an unreliable indicator of mycobacterial virulence. Infect Immun. 1999; 67(10):5483-5. PMC: 96910. DOI: 10.1128/IAI.67.10.5483-5485.1999. View

Lagranderie M, Balazuc A, Deriaud E, Leclerc C, Gheorghiu M . Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains. Infect Immun. 1996; 64(1):1-9. PMC: 173719. DOI: 10.1128/iai.64.1.1-9.1996. View

Lurie M, Abramson S, HEPPLESTON A . On the response of genetically resistant and susceptible rabbits to the quantitative inhalation of human type tubercle bacilli and the nature of resistance to tuberculosis. J Exp Med. 1952; 95(2):119-34. PMC: 2212059. DOI: 10.1084/jem.95.2.119. View

HABEL K . Tuberculosis in a laboratory monkey colony; its spread and its control. Am Rev Tuberc. 2010; 55(1):77-92. DOI: 10.1164/art.1947.55.1.77. View

Stead W . Variation in vulnerability to tuberculosis in America today: random, or legacies of different ancestral epidemics?. Int J Tuberc Lung Dis. 2001; 5(9):807-14. View

10.

Crampin A, Glynn J, Fine P . What has Karonga taught us? Tuberculosis studied over three decades. Int J Tuberc Lung Dis. 2009; 13(2):153-64. PMC: 3272402. View

11.

Lewinsohn D, Winata E, Swarbrick G, Tanner K, Cook M, Null M . Immunodominant tuberculosis CD8 antigens preferentially restricted by HLA-B. PLoS Pathog. 2007; 3(9):1240-9. PMC: 2323292. DOI: 10.1371/journal.ppat.0030127. View

12.

Hemsworth G, Kochan I . Secretion of antimycobacterial fatty acids by normal and activated macrophages. Infect Immun. 1978; 19(1):170-7. PMC: 414063. DOI: 10.1128/iai.19.1.170-177.1978. View

13.

Shigenaga T, Dannenberg A, Lowrie D, Said W, URIST M, Abbey H . Immune responses in tuberculosis: antibodies and CD4-CD8 lymphocytes with vascular adhesion molecules and cytokines (chemokines) cause a rapid antigen-specific cell infiltration at sites of bacillus Calmette-Guérin reinfection. Immunology. 2001; 102(4):466-79. PMC: 1783201. DOI: 10.1046/j.1365-2567.2001.01195.x. View

14.

Lewinsohn D, Tydeman I, Frieder M, Grotzke J, Lines R, Ahmed S . High resolution radiographic and fine immunologic definition of TB disease progression in the rhesus macaque. Microbes Infect. 2006; 8(11):2587-98. DOI: 10.1016/j.micinf.2006.07.007. View

15.

Rook G, Dheda K, Zumla A . Immune responses to tuberculosis in developing countries: implications for new vaccines. Nat Rev Immunol. 2005; 5(8):661-7. DOI: 10.1038/nri1666. View

16.

Rook G, Seah G, Ustianowski A . M. tuberculosis: immunology and vaccination. Eur Respir J. 2001; 17(3):537-57. DOI: 10.1183/09031936.01.17305370. View

17.

Dorman S, Hatem C, Tyagi S, Aird K, Lopez-Molina J, Pitt M . Susceptibility to tuberculosis: clues from studies with inbred and outbred New Zealand White rabbits. Infect Immun. 2004; 72(3):1700-5. PMC: 356026. DOI: 10.1128/IAI.72.3.1700-1705.2004. View

18.

Horwitz M, Harth G, Dillon B, Maslesa-Galic S . Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein. Infect Immun. 2005; 73(8):4676-83. PMC: 1201189. DOI: 10.1128/IAI.73.8.4676-4683.2005. View

19.

Comstock G . Field trials of tuberculosis vaccines: how could we have done them better?. Control Clin Trials. 1994; 15(4):247-76. DOI: 10.1016/0197-2456(94)90042-6. View

20.

Smith D, McMurray D, WIEGESHAUS E, GROVER A, Harding G . Host-parasite relationships in experimental airborne tuberculosis. IV. Early events in the course of infection in vaccinated and nonvaccinated guinea pigs. Am Rev Respir Dis. 1970; 102(6):937-49. DOI: 10.1164/arrd.1970.102.6.937. View